tbuckley/cabot-search huggingface dataset:
UN climate chief attacks billions spent on subsidising fossil fuels
Authors: John Vidal
Journal: BMJ (2015)

Health has moved upstage in climate talks in Paris this week as vulnerable countries, UN bodies, and civil society groups press for a more ambitious deal to reduce greenhouse gas emissions.

As diplomats from 195 countries work to negotiate a final text ahead of the arrival of decision makers next week, negotiations have underlined the disastrous long term effects on health of a rise in global temperatures.

The powerful Like Minded Developing Countries (LMDC) group, which includes China and India, has pressed for health to be included in two key areas of the final text. “We support a right to health,” said Gurdiaz Nijar, a spokesman for the group. 

The World Health Organization said, …
3D‐Printed Biodegradable Polymeric Vascular Grafts
Authors: Anthony J. Melchiorri, Narutoshi Hibino, C. A. Best, T. Yi, Y. U. Lee, C. A. Kraynak, Lucas K. Kimerer, A. Krieger, P. Kim, Christopher K. Breuer, John P. Fisher
Journal: Advanced Healthcare Materials (2015)

Congenital heart defect interventions may benefit from the fabrication of patient-specific vascular grafts because of the wide array of anatomies present in children with cardiovascular defects. 3D printing is used to establish a platform for the production of custom vascular grafts, which are biodegradable, mechanically compatible with vascular tissues, and support neotissue formation and growth. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
CRISPR Critters and CRISPR Cracks
Authors: R. Alta Charo, Henry T. Greely
Journal: The American Journal of Bioethics (2015)

This essay focuses on possible nonhuman applications of CRISPR/Cas9 that are likely to be widely overlooked because they are unexpected and, in some cases, perhaps even "frivolous." We look at five uses for "CRISPR Critters": wild de-extinction, domestic de-extinction, personal whim, art, and novel forms of disease prevention. We then discuss the current regulatory framework and its possible limitations in those contexts. We end with questions about some deeper issues raised by the increased human control over life on earth offered by genome editing.
IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration
Authors: Upasana Kulkarni, Christian M. Karsten, Thomas Kohler, Sven Hammerschmidt, Kurt Bommert, Benjamin Tiburzy, Lingzhang Meng, Lara Thieme, Andreas Recke, Ralf J. Ludwig, Karolin Pollok, Kathrin Kalies, Bjarne Bogen, Martin Boettcher, Thomas Kamradt, Anja E. Hauser, Christian Langer, Markus Huber-Lang, Fred D. Finkelman, Jörg Köhl, David M. Wong, Rudolf Armin Manz
Journal: Journal of Allergy and Clinical Immunology (2015)
A Pilot Study to Evaluate the Efficacy of Class IV Lasers on Nonhealing Neuroischemic Diabetic Foot Ulcers in Patients With Type 2 Diabetes
Authors: Giuseppe Maltese, Janaka Karalliedde, Helen Rapley, Tim Amor, Alpa Lakhani, Luigi Gnudi
Journal: Diabetes Care (2015)

Diabetic foot ulcers (DFUs) represent a disabling complication of diabetes that has a devastating impact on the quality of life and predict lower-limb amputation and premature mortality (1). Despite best practice, 30–40% of DFUs do not heal within 12–20 weeks (2). Novel therapeutic agents have been tested in clinical trials, and it has been estimated that ∼30–50% of patients with neuropathic DFUs receiving these new treatments have healed by 12–20 weeks (3). Laser therapy, delivered with devices emitting one or two wavelengths, has been reported as an adjunctive procedure that promotes the healing of chronic diabetic wounds by increasing the blood flow and the release of growth factors and by reducing the inflammation (4).

In this pilot study, we have been the first to investigate the efficacy of an advanced class IV …
Poseidon Phase I/II Trial: Abituzumab Combined with Cetuximab Plus Irinotecan As Second-Line Treatment for Patients with Kras Wild-Type Metastatic Colorectal Cancer
Authors: E. Élez, I. Kocáková, T. Höhler, U.M. Martens, C. Bokemeyer, E. Van Cutsem, B. Melichar, M. Smakal, T. Cso˝szi, E. Topuzov, R. Orlova, S. Tjulandin, F. Rivera, J. Straub, R. Bruns, S. Quaratino, J. Tabernero
Journal: Annals of Oncology (2014)
Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample
Authors: Alfredo Ramos-Miguel, Christa Hercher, Clare L. Beasley, Alasdair M. Barr, Thomas A. Bayer, Peter Falkai, Sue E. Leurgans, Julie A. Schneider, David A. Bennett, William G. Honer
Journal: Molecular Neurodegeneration (2015)

Presynaptic terminals contribute to cognitive reserve, balancing the effects of age-related pathologies on cognitive function in the elderly. The presynaptic protein Munc18-1, alternatively spliced into long (M18L) or short (M18S) isoforms, is a critical modulator of neurotransmission. While subtle alterations in Munc18-1 have been shown to cause severe neuropsychiatric disorders with cognitive impairment, little information is known regarding the specific roles of Munc18-1 splice variants. We first investigated functional and anatomical features evidencing the divergent roles of M18L and M18S, and then evaluated their contribution to the full range of age-related cognitive impairment in the dorsolateral prefrontal cortex of a large sample of participants from a community-based aging study, including subjects with no-(NCI, n = 90), or mild-(MCI, n = 86) cognitive impairment, or with clinical dementia (n = 132). Finally, we used APP23 mutant mice to study the association between M18L/S and the time-dependent accumulation of common Alzheimer's disease pathology. Using isoform-specific antibodies, M18L was localized to the synaptosomal fraction, with a distribution matching lipid raft microdomains. M18S was found widely across cytosolic and synaptosomal compartments. Immunocytochemical studies identified M18L in perisomatic, GABAergic terminals, while M18S was broadly distributed in GABAergic and glutamatergic terminals. Using regression models taking into account multiple age-related pathologies, age, education and sex, global cognitive function was associated with the level of M18L (p = 0.006) but not M18S (p = 0.88). Mean M18L in dementia cases was 51 % lower than in NCI cases (p < 0.001), and each unit of M18L was associated with a lower likelihood of dementia (odds ratio = 0.68, 95 % confidence interval = 0.50–0.90, p = 0.008). In contrast, M18S balanced across clinical and pathologically diagnosed groups. M18L loss may not be caused by age-related amyloid pathology, since APP23 mice (12- and 22-months of age) had unchanged cortical levels of M18L/S compared with wild-type animals. M18L was localized to presynaptic inhibitory terminals, and was associated with cognitive function and protection from dementia in an elderly, community-based cohort. Lower M18L in inhibitory presynaptic terminals may be an early, independent contributor to cognitive decline.
Walker Carcinosarcoma 256 Tissue as a Dietary Constituent. I. Stimulation of Appetite and Growth in the Tumor-bearing Rat
Authors: Florence K. Millar, Julius White, Robin H. Brooks, G. Burroughs Mider
Journal: JNCI Journal of the National Cancer Institute (1957)

Walker Carcinosarcoma 256 Tissue as a Dietary Constituent. I. Stimulation of Appetite and Growth in the Tumor-bearing Rat Get access Florence K. Millar, Florence K. Millar National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Julius White, Julius White National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Robin H. Brooks, Robin H. Brooks National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar G. Burroughs Mider G. Burroughs Mider National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 5, November 1957, Pages 957–967, https://doi.org/10.1093/jnci/19.5.957 Published: 01 November 1957 Article history Received: 09 July 1957 Published: 01 November 1957
Studies on Fractions of a Mouse Thymoma: Effect of Diet and Inhibiting Agents on the Lipid and Nucleic Acid Concentrations&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: T. N. Warren, Alfred Chanutin
Journal: JNCI Journal of the National Cancer Institute (1948)

Journal Article Studies on Fractions of a Mouse Thymoma: Effect of Diet and Inhibiting Agents on the Lipid and Nucleic Acid Concentrations Get access T. N. Warren, T. N. Warren Search for other works by this author on: Oxford Academic PubMed Google Scholar Alfred Chanutin Alfred Chanutin Biochemical Laboratory, University of Virginia, Charlottesville, Va. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 1, August 1948, Pages 47–53, https://doi.org/10.1093/jnci/9.1.47 Published: 01 August 1948 Article history Received: 11 May 1948 Published: 01 August 1948
Photodynamic Quenched Cathepsin Activity Based Probes for Cancer Detection and Macrophage Targeted Therapy
Authors: Yael Ben-Nun, Emmanuelle Merquiol, Alexander Brandis, Boris Turk, Avigdor Scherz, Galia Blum
Journal: Theranostics (2015)

Elevated cathepsins levels and activities are found in several types of human cancer, making them valuable biomarkers for detection and targeting therapeutics.We designed small molecule quenched activity-based probes (qABPs) that fluoresce upon activity-dependent covalent modification, yielding cell killing by Photodynamic Therapy (PDT).These novel molecules are highly selective theranostic probes that enable both detection and treatment of cancer with minimal side effects.Our qABPs carry a photosensitizer (PS), which is activated by light, resulting in oxidative stress and subsequent cell ablation, and a quencher that when removed by active cathepsins allow the PS to fluoresce and demonstrate PD properties.Our most powerful and stable PS-qABP, YBN14, consists of a selective cathepsin recognition sequence, a QC-1 quencher and a new bacteriochlorin derivative as a PS.YBN14 allowed rapid and selective non-invasive in vivo imaging of subcutaneous tumors and induced specific tumor macrophage apoptosis by light treatment, resulting in a substantial tumor shrinkage in an aggressive breast cancer mouse model.These results demonstrate for the first time that the PS-qABPs technology offers a functional theranostic tool, which can be applied to numerous tumor types and other inflammation-associated diseases.
Alternative Treatment Approaches to Early Stage or Unresectable Hepatocellular Carcinoma Confined to the Liver
Authors: Francesco Izzo, Francesco Fiore, Carlo De Werra, Steven A. Curley
Journal: Liver Cancer (1998)

As noted in Chapter 2, most patients diagnosed with hepatocellular cancer (HCC) are not candidates for resection. In some patients unresectability is based on the presence of extrahepatic metastasis at the time of diagnosis. Many more patients with HCC confined to the liver are not candidates for resection because of large tumor size, multicentricity, adjacency or direct invasion to major blood vessels, or concomitant cirrhosis with inadequate functional hepatic reserve.KeywordsRadiofrequency AblationTranscatheter Arterial EmbolizationPercutaneous Ethanol InjectionMicrowave AblationMetastatic Liver TumorThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin
Authors: A.J. Gelderblom, W.J. Loos, M.J.A. de Jonge, A. Sparreboom, A.S.T. Planting, M.E.L. van der Burg, E. Brouwer, C. Verheij, L. Ouwens, S. Hearn, J. Verweij
Journal: Annals of Oncology (2000)

Based on in vitro observations showing more pronounced antitumour efficacy with protracted exposure of topoisomerase I inhibitors at low concentration, and since oral delivery is a more convenient method for prolonged drug administration, and preferred by patients [1, 2], an oral formulation of topotecan was developed. Topotecan, supplied in gelatin capsules, has an absolute bioavailability of 42% ± 13% [3]. The maximally tolerated dose for oral topotecan, administered for 5 days every 21 days as a single agent was defined as 2.3 mg/m/day, with myelosuppression (in particular neutropenia) as the dose limiting toxicity [4]. Two randomised studies on single agent topotecan suggested that the oral formulation is equipotent to the intravenous formulation in patients with ovarianand small-cell lung cancer, whilst associated with less grade 3 and 4 neutropenia [5, 6]. Recently, a phase I study combining oral topotecan (T) given for five days every three weeks with cisplatin (C) at 75 mg/m on day 1 (sequence CT) or day 5 (sequence TC) was completed [7], In congruency with the results of the study by Rowinsky with i.v. topotecan [8], the maximum tolerated dose (MTD) for topotecan in the CT sequence of 1.25 mg/m/day x 5 was considerably lower than that for the alternate sequence (2 mg/m/day x 5). Cisplatin was not observed to have an effect on the pharmacokinetics of topotecan [7]. Finally, topotecan systemic exposure was directly associated with antitumour activity in in vivo studies [9]. Given this apparent relationship between topotecan systemic exposure and clinical response, we tried to increase the topotecan dose in the combination cisplatinoral topotecan by using a lower cisplatin dose. We performed a phase I study in patients with solid tumours with oral topotecan preceded by a fixed dose of i.v. cisplatin at 50 mg/m. Patients and methods
La rougeole en France : impact épidémiologique d'une couverture vaccinale sub-optimale
Authors: I Bonmarin, D Lévy-Bruhl
Journal: Eurosurveillance (2002)

La promotion de la vaccination en France depuis 1983 a abouti a une reduction de 97% de la morbidite et de 60% de la mortalite de la rougeole. Cependant, le taux de couverture stagnant et sub-optimal a 84% entraine un deplacement de l’âge des cas dans des tranches ou les complications sont plus frequentes et severes. Ainsi, la proportion des plus de 10 ans est passee de 13% en 1985 a 48% en 1997, la transmission de la rougeole se maintenant en France. Pour eliminer la maladie, une couverture vaccinale a 2 doses et a plus de 95% serait necessaire.
Renal vascular morphology in male Dahl rats on high-salt diet
Authors: X Wu, J W Scholey, H Sonnenberg
Journal: Journal of the American Society of Nephrology (1996)

Inbred Dahl salt-sensitive (S) and sal-resistant (R) rats were fed with either high (4% K; HK) or low (0.2% K; LK) potassium diets (both contained 8% salt, 2.5% calcium, 0.8% magnesium, and 2.0% PO4) for 4 wk. During the last week, systolic blood pressure was measured in conscious animals. External diameter of renal vessels (ED) was used to divide renal vessels into four subgroups: less than 25 microns; greater than 25 microns but less than 55 microns; greater than 55 microns but less than 150 microns; and greater than 150 microns. Luminal diameter (LD), cross-sectional wall area (WAC) and wall-tolumen ratio (W/L) were measured or calculated. Glomerular volume (VG) was measured. Data showed that blood pressures of S rats were significantly higher than those of R rats on both diets. Reduced dietary potassium was associated with increased blood pressure in both strains. Changes in renal vessels were characterized by bigger lumen and greater wall area in S rats, compared with R rats, especially in the smallest vessels. Low potassium intake was associated with reduced lumen diameter and enlarged W/L ratio with or without changing WAC in both strains. VG showed no significant differences between strains or between diets. It was concluded that in addition to the genetically determined differences in renal vascular structure between S and R rats, dietary potassium depletion may engender further renal injury, exacerbating hypertension.
Three Different Chemotherapy Combinations with Concurrent Thoracic Radiation for Patients with Stage III Non-Small Cell Lung Cancer
Authors: M. Ozcelik, O. Balvan Ercelep, A. Guven Mert, S. Yuksel, P. Ozdemir, H. Surmeli, D. Isık, D. Aydin, T. Korkmaz, H. Odabas, M. Aliustaoglu, C. Gemici, A. Mayadagli, M. Gumus
Journal: Annals of Oncology (2014)
A Randomized Trial of Adjuvant Combination Chemotherapy With Or Without Prednisone in Premenopausal Breast Cancer Patients With Metastases in One to Three Axillary Lymph Nodes
Authors: A. Goldhirsch, J. Stjemsward, W. Hartmann, B. Davis, D. Zava, V. C. Jordan, A. Zimmermann, A. H. Baggenstoss, C. Wiedmer, C. Ramminger, R. Gelber, K. Price, K. Stanley, M. Zelen, M. Istey, M. Parsons, L. Szymoniak, P. Helman, A. Hacking, A. Gudgeon, A. Tiltman, E. Dowdle, C. G. Schmidt, R. Zchaber, F. Schning, K. Hköffken, L. D. Leder, H. Ludwig, R. Cailles, C. M. Rudenstam, J. Save-Soderbergh, E. Cahlin, C. Johnsen, J. Mattsson, H. Salander, J. O. Svensson, S. Nilsson, J. Pomander, L. Mattsson, C. G. Bäckstrom, S. Bergegardh, S. Dahlin, N. Fahl, Y. Hessman, S. Holmberg, O. Ruusvik, L. Niklasson, U. Ljungqvist, C. Andersson, L. Ivarsson, J. Mark, G. Ostberg, I. Dahl
Journal: Cancer Research (1985)

The impact of adding low-dose continuous prednisone (7.5 mg daily) to an adjuvant cyclophosphamide-methotrexate-5-fluorouracil chemotherapy regimen was investigated in a randomized trial of 505 pre- and perimenopausal patients with operable breast cancer and one to three axillary lymph node mA©tastases (Ludwig Breast Cancer Study I). As a consequence of lower hematological toxicity a significantly higher dose of cyclophosphamide-methotrexate-5-fluorouracil could be administered with added prednisone (P < 0.0001). However, at a median followup of 48 months, no improvement in terms of disease-free survival (P = 0.35) or overall survival (P = 0.73) was observed. Induced amenorrhea was associated with a longer disease-free survival for younger patients, patients who received lower cyclo1Members of the Ludwig Breast Cancer Study Group are listed by institution.
Biopharmaceutics classification system (BCS)-based biowaiver for immediate release solid oral dosage forms of moxifloxacin hydrochloride (Moxiflox GPO) manufactured by the Government Pharmaceutical Organization (GPO)
Authors: Nawaphon Saelim, Khemjira Suksawaeng, Jutamat Chupan, Isariya Techatanawat
Journal: Asian Journal of Pharmaceutical Sciences (2015)
Characteristics of 77 Puerto Ricans who attempted suicide
Authors: B Fernandez-Pol
Journal: American Journal of Psychiatry (1986)

Seventy-seven patients of Puerto Rican origin who had attempted suicide and were admitted to the inpatient psychiatric unit of a general hospital were administered the Schedule for Affective Disorders and Schizophrenia (SADS), selected items of the Life Crisis Inventory, and the Beck Depression Inventory. Their scores on the SADS medical lethality and suicidal intent scales were in the minimal range, and their Beck inventory scores were in the mild range. Logistic regression analyses showed that alcohol and other substance abuse was a significant predictor of attempted suicide; place of birth (Puerto Rico versus the continental United States) was not.
How Mainstream Medicine Sees Photodynamic Therapy in the United Kingdom
Authors: Stephen G. Bown
Journal: Journal of the National Comprehensive Cancer Network (2012)

Although photodynamic therapy (PDT) has been used successfully to treat an assortment of different types of cancer, it has yet to reach the level of mainstream medicine on either side of the Atlantic. Unsubstantiated claims of PDT’s efficacy in the past may be part of the reason for this. However, perhaps the main obstacle to PDT’s endorsement by conventional medicine is the limited number of high-quality randomized controlled trials (RCTs) comparing it with relevant comparators for all meaningful outcomes, including effectiveness, safety, adverse events, quality of life, survival, and cost. Based on a Health Technology Assessment report on the current status of PDT and consultation with professional groups, specialist societies, and clinical study groups in the United Kingdom, this article explores the current clinical guidelines for use of PDT in cancer treatment and the dearth of supportive data from RCTs.
AB0595 Evaluation of Cognitive Function by Electrophysiological Study in Systemic Lupus Erythematosus Patients with Previous Neuropsychiatric Involvement
Authors: Y. Gao, T.F. Cheung, J. Gao, E. Lau, H.Y. Wan, M.Y. Mok
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Previous studies on cognitive dysfunction evaluated by electrophysiological test in patients with systemic lupus erythematosus (SLE) who had previous neuropsychiatric involvement (NPSLE) were inconsistent. <h3>Objectives</h3> This study aimed to evaluate P300 as an electrophysiological marker of cognitive function in NPSLE patients who were diagnosed to have cognitive impairment by standard neuropsychological tests. <h3>Methods</h3> Event-related potentials (ERP) were assessed by the auditory and visual oddball paradigms. Amplitude and latency of P300 at the frontal (Fz), central (Cz) and parietal (Pz) regions were determined and compared to controls. <h3>Results</h3> Sixteen patients with previous NPSLE were identified to have cognitive impairment, defined as one or more tests below 2 standard deviations of demographically normative data, among 20 patients recruited for comprehensive neuropsychological tests. P300 detection was performed in NPSLE patients with cognitive impairment (n=9), matched SLE patients without previous NPSLE (non-NPSLE) (n=9), and healthy controls (n=15). Auditory oddball task did not show any P300 abnormality between groups. Visual oddball task revealed reduced amplitude of P300 over Fz (p=0.002) and Cz (p=0.009) electrodes in NPSLE patients compared to healthy controls and among those who had predominant memory deficit (p=0.01 at Fz). Abnormal P300 was also observed in non-NPSLE patients at Fz and Cz. <h3>Conclusions</h3> P300 elicited by auditory oddball paradigm was not a sensitive electrophysiological marker for cognitive impairment in NPSLE patients. Using visual oddball paradigm, abnormal P300 was found in NPSLE patients over frontal and parietal regions compared to normal controls but was not discriminative from possible subclinical disease in non-NPSLE patients. <h3>Disclosure of Interest</h3> None declared
Phase III Recourse Trial of Tas-102 Vs. Placebo, with Best Supportive Care (Bsc), in Patients (Pts) with Metastatic Colorectal Cancer (Mcrc) Refractory to Standard Therapies
Authors: E. Van Cutsem, A. Ohtsu, A. Falcone, T. Yoshino, R. Garcia-Carbonero, N. Mizunuma, K. Yamazaki, Y. Shimada, J. Tabernero, Y. Komatsu, A. Sobrero, E. Boucher, M. Peeters, B. Tran, H. Lenz, A. Zaniboni, H. Hochster, M. Aivado, L. Makris, R. Mayer
Journal: Annals of Oncology (2014)